Immune Reconstitution

Division Of Basic Sciences - Nci

Investigators

Linked publications, trials & patents

Abstract

Previously we have: 1) identified a novel CAR-T cell therapy for chronic lymphocytic leukemia (CLL) and establish Siglec-6 as a possible target for immunotherapy; 2) shown that the NK-CAR framework improves the activity of CARs in NK cells and that CD5 would be a better target than CD3 for T-cell malignancies, as dynamic downregulation of target expression may affect in vivo efficacy; 3) revealed a previously unappreciated role for CCR9 in the tissue homeostasis and effector function of CD4 T cells in the gut; and 4) demonstrated that the abundance of IL-7, and not IL-15, limits the size of the peripheral iNKT cell pool. These results redefine the cytokine requirement for iNKT cells and indicate competition for IL-7 between iNKT and conventional alpha-beta T cells. Work on this project was concluded in FY23.